Targeted alpha therapy of mCRPC: Dosimetry estimate of $^{213}$Bismuth-PSMA-617

Clemens Kratochwil1 · Karl Schmidt2 · Ali Afshar-Oromieh1 · Frank Bruchertseifer3 · Hendrik Rathke1 · Alfred Morgenstern3 · Uwe Haberkorn1,4 · Frederik L. Giesel 1

Received: 23 May 2017 / Accepted: 22 August 2017 / Published online: 11 September 2017 © The Author(s) 2017. This article is an open access publication

Abstract

Purpose PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA). In this work, we estimate the radiation dosimetry for this ligand labeled with the alpha-emitter $^{213}$Bi.

Methods Three patients with metastatic prostate cancer underwent PET scans 0.1 h, 1 h, 2 h, 3 h, 4 h and 5 h after injection of $^{68}$Ga-PSMA-617. Source organs were kidneys, liver, spleen, salivary glands, bladder, red marrow and representative tumor lesions. The imaging nuclide $^{68}$Ga was extrapolated to the half-life of $^{213}$Bi. The residence times of $^{213}$Bi were forwarded to the instable daughter nuclides. OLINDA was used for dosimetry calculation. Results are discussed in comparison to literature data for $^{225}$Ac-PSMA-617.

Results Assuming a relative biological effectiveness of 5 for alpha radiation, the dosimetry estimate revealed equivalent doses of mean 8.1 Sv$_{RBE5}/$GBq for salivary glands, 8.1 Sv$_{RBE5}/$GBq for kidneys and 0.52 Sv$_{RBE5}/$GBq for red marrow. Liver (1.2 Sv$_{RBE5}/$GBq), spleen (1.4 Sv$_{RBE5}/$GBq), bladder (0.28 Sv$_{RBE5}/$GBq) and other organs (0.26 Sv$_{RBE5}/$GBq) were not dose-limiting. The effective dose is 0.56 Sv$_{RBE5}/$GBq. Tumor lesions were in the range 3.2–9.0 Sv$_{RBE5}/$GBq (median 7.6 Sv$_{RBE5}/$GBq). Kidneys would limit the cumulative treatment activity to 3.7 GBq; red marrow might limit the maximum single fraction to 2 GBq. Despite promising results, the therapeutic index was inferior compared to $^{225}$Ac-PSMA-617.

Conclusions Dosimetry of $^{213}$Bi-PSMA-617 is in a range traditionally considered reasonable for clinical application. Nevertheless, compared to $^{225}$Ac-PSMA-617, it suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSMA-617 in dose-limiting organs than the physical half-life of $^{213}$Bi, rendering this nuclide as a second choice radiolabel for targeted alpha therapy of prostate cancer.

Keywords Bi-213 · Targeting alpha therapy · PSMA · Prostate cancer

Introduction

A survival benefit observed in bone metastatic prostate cancer after alpha radiation therapy with the bone-seeking $^{223}$RaCl$_2$, which could not be demonstrated for its beta-emitting analogue $^{89}$SrCl$_2$, increased the interest in alpha-emitter-based radionuclide therapy [1]. However, $^{223}$RaCl$_2$ accumulates in the bone remodeling zone of metastases and hits tumor cells only indirectly and insufficiently; extra-osseous lesions are not treated at all. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells [2]. PSMA-targeting radio-ligand therapy (RLT) based on the beta-emitting $^{177}$Lu-PSMA-617 has been reported as being well-tolerated and presents promising anti-tumor activity [3]. More recently, initial results with targeting alpha therapy (TAT) based on $^{225}$Ac-PSMA-617 imply even higher anti-tumor...
activity and less hematological toxicity in case of diffuse red marrow infiltration [4, 5]. $^{213}$Bi is another alpha particle-emitting nuclide already used in clinical application [6–8]. Tagged to the PSMA-mAB J591, $^{213}$Bi demonstrated promising efficacy in particular against prostate cancer in the preclinical setting [9, 10]. In comparison to $^{225}$Ac ($T_{1/2} 9.9$ days), due to its short physical half-life, rapid tumor targeting is more pivotal with $^{213}$Bi ($T_{1/2} 46$ min). However, the low-molecular-weight PSMA-617 demonstrates fast pharmacokinetics in both animals [2] and human beings [11], and led to the discussion whether $^{213}$Bi can serve as an alternative to $^{225}$Ac for PSMA-617. Recently, a single case of promising anti-tumor activity of $^{213}$Bi-PSMA-617 was reported [12]. Using $^{68}$Ga ($T_{1/2} 68$ min) as a surrogate nuclide enabling high-resolution quantitative $^{68}$Ga-PSMA-617 PET-imaging, we estimated the extrapolated radiation dosimetry for $^{213}$Bi-PSMA-617 and compared its therapeutic index with findings for $^{225}$Ac-PSMA-617.

**Methods**

**Patients**

The used imaging data sets have already been used to calculate the dosimetry estimate of $^{68}$Ga-PSMA-617 as a diagnostic agent as part of an evaluation approved by the local ethics committee and including written informed consent [11]. These anonymized data were evaluated for extrapolation of dosimetry to $^{213}$Bi. No additional experiments involving human beings were required for this work.

Detailed patients characteristics are provided in the supplement (Supplement/Table 1). All study subjects had a moderate total tumor volume; creatinine values were in the normal range, respectively. Thus, our results may not apply for patients with underlying kidney disease or excessive tumor burden.

**Imaging**

Exams were performed in a BIOGRAPH-mCT PET/CT scanner (Siemens). An unenhanced low-dose CT scan [120 keV/60 mAs at 3 h and 80 keV/30 mAs at other time points; 5-mm slice thickness, 2-mm increment, B31 (Siemens) soft-tissue reconstruction kernel] was obtained at 0.1 h, 1 h, 2 h, 3 h, 4 h and 5 h after injection of 213–260 MBq $^{68}$Ga-PSMA-617 immediately followed by a whole-body (vertex to upper legs) PET in 3-dimensional mode (matrix $200 \times 200$). Each bed position (axial field of view, 16.2 cm) was acquired for 3 min. The emission data were corrected for random, scatter and attenuation. Reconstruction was conducted with an ordered-subset expectation maximization algorithm with two iterations and eight subsets and Gauss-filtered with 2 mm in full width at half maximum. Urine was collected before each PET/CT measurement and venous blood samples were taken. For illustrative purposes, the decay-corrected PET images, presented in linear gray scale and normalized to the time point 2 h p.i., were used to calculate quantitatively correct shadings taking into account the physical half-life of $^{213}$Bi and $^{225}$Ac.

**Dosimetry calculation**

The dosimetry analysis was performed using the QDOSE dosimetry software suite (ABX-CRO Advanced Pharmaceutical Services, Dresden, Germany). All six imaging time points were coregistered with automatic rigid and, if applicable, deformable coregistration of CT images. PET scans were coregistered by coupling to the transformation matrix of the coupled CT. Segmentation was done by a radiologist, who defined the organ edges on the CT images. To simplify the drawing process, preliminary volumes of interest (VOIs) for kidneys, liver, spleen, parotid glands, submandibular glands and urinary bladder were first drawn manually and then the “percent of maximum threshold” of an automatically adapted VOI in the corresponding PET images was varied, until the VOI matched the morphological delineated organ contour. The VOIs were then copied onto all other time points to generate the time-activity curves (TACs) for all segmented organs, respectively. A VOI covering the complete field of view was used as a surrogate to calculate the effective half-life in the total body, assuming that the distant limbs (cropped during PET/CT imaging) behave similarly as the trunk-torso. This effective half-life was then applied to the injected activity to derive the total body TAC. The TACs for red marrow were based on venous blood samples following established models [13, 14], excluding patient 1 due to missing values caused by poor vein conditions. The urinary bladder content TAC was a combination of estimated activity in the urinary bladder content VOI in the PET images and measured activity of five collections of voided urine. The activity of $^{68}$Ga at each TAC time point was corrected for physical decay (T1/2 68 min) since time of injection. Then, the decay formula was applied vice versa with T1/2 46 min from time of injection to the respective time point to calculate the activity of $^{213}$Bi. Thus, TACs intended to represent $^{213}$Bi-PSMA-617 were calculated, taking into account the different half-life of the modeled radionuclide but assuming that the nuclide replacement does not affect the pharmacokinetics of the shuttle molecule. Red marrow, total body, urinary bladder content and all segmented organ TACs (Supplement/Table 2) were loaded into QDOSE to be considered in further calculations. Curve fitting was then applied to all organ TACs. For all cases, a mono-exponential curve fit was used. If possible, all time points or time points 2 to 6 were used for the curve fit. In salivary glands, lesions and kidneys, an increasing uptake...
during the first three time points was observed, leading to an effective half-life greater than the physical half-life. In those cases, only the last three to six time points were used for curve fitting. Activity integration was done assuming a linear increase from 0 to the first measured activity, using trapezoidal approximation between the first and last measured time point and from the last measured time point to infinity using the fitted function. The remainder body was calculated by subtracting all source organs from total body. Residence times were calculated by dividing the cumulated activity with the injected activity. The $^{213}$Bi residence times of all included source organs and remainder body were used for equivalent dose calculation in OLINDA [15] using the original organ masses of the “adult male” phantom, as only selective patients without morphological abnormalities have been chosen for this modeling. The doses absorbed to the salivary glands and tumor lesions were determined using the spherical model [16].

The same residence time of $^{213}$Bi was used to calculate equivalent doses for all daughter nuclides ($^{209}$Tl, $^{213}$Po and $^{209}$Pb) in OLINDA. The finally absorbed and effective doses are the sum of these nuclides, weighting $^{209}$Tl with 2% and $^{213}$Po with 98%, following the decay scheme of $^{213}$Bi (Fig. 1) [25]. For $^{209}$Pb, 100% of the initial $^{213}$Bi residence time was used again. We assumed instant decay, i.e. a possible translocation of daughter nuclides between the succeeding disintegrations was neglected, which can be justified due to the short 3.7-μs half-life of $^{213}$Po in the main decay branch and the limited contribution of the low-energy beta-emitter $^{209}$Pb to the summed absorbed dose.

The calculated absorbed doses were translated into equivalent doses using weighting factors of 5 for alpha and 1 for beta–gamma radiation, from now on, referred to as “$SV_{RBE5}$”. The concept of the relative biological effectiveness (RBE) of alpha radiation with regard to deterministic effects was reviewed in detail by the US Department of Energy [17] and the Committee on Medical Internal Radiation Dose [18], which came to the conclusion that an RBE = 5 presents the most reasonable assumption for the 8.4 MeV alpha particle energy predominantly emitted during decay of $^{213}$Bi. The uncertainties within this concept have already been discussed with regard to $^{225}$Ac-PSMA-617 [5]. However, the consistent application of model assumptions is helpful to improve the comparability with the literature values for the $^{225}$Ac-PSMA-617 benchmark [5].

![Decay schema of $^{213}$Bi](image-url)

Fig. 1 Decay schema of $^{213}$Bi

### Results

Interim results, such as residence time, biological and effective half-life, are provided in the Supplement/Table 3. The dose approximation from the last measured time point to infinity contributed <5% to the cumulated activity, putting aside the need for more sophisticated techniques than monoeponential curve fitting. The finally calculated safety dosimetry for normal organ radiation exposure in equivalent doses is presented in Table 1. The dose contributions for the respective decay steps, as illustrated in Fig. 1, are presented in detail within the Supplement/Table 4.

Projected equivalent doses for salivary glands (which is not provided by OLINDA because they have not been considered in the Cristy–Eckerman phantom) and mean values for estimated tumor equivalent doses were calculated using the spherical model (interim results presented in the Supplement/Table 5). They are presented in Table 2, along with a brief comparison to our results for dosimetry modeling of $^{225}$Ac-PSMA-617,

| Organ                   | Equivalent dose ($SV_{RBE5}/GBq$, mean ± SD) |
|-------------------------|-----------------------------------------------|
| Adrenals                | 0.27 ±0.02                                    |
| Brain                   | 0.27 ±0.02                                    |
| Breasts                 | 0.27 ±0.02                                    |
| Gallbladder wall        | 0.27 ±0.02                                    |
| LLI wall                | 0.27 ±0.02                                    |
| Small intestine         | 0.27 ±0.02                                    |
| Stomach wall            | 0.27 ±0.02                                    |
| ULI wall                | 0.27 ±0.02                                    |
| Heart wall              | 0.27 ±0.02                                    |
| Kidneys                 | 8.11 ±1.80                                    |
| Liver                   | 1.20 ±0.12                                    |
| Lungs                   | 0.27 ±0.02                                    |
| Muscle                  | 0.27 ±0.02                                    |
| Ovaries                 | 0.27 ±0.02                                    |
| Pancreas                | 0.27 ±0.02                                    |
| Red marrow              | 0.52 ±0.15                                    |
| Osteogenic cells        | 3.55 ±0.77                                    |
| Skin                    | 0.27 ±0.02                                    |
| Spleen                  | 1.42 ±0.02                                    |
| Testes                  | 0.27 ±0.02                                    |
| Thymus                  | 0.27 ±0.02                                    |
| Thyroid                 | 0.27 ±0.02                                    |
| Urinary bladder wall    | 0.28 ±0.03                                    |
| Uterus                  | 0.27 ±0.02                                    |
| Total body              | 0.34 ±0.02                                    |
| Effective dose equivalent| 0.99 ±0.09                                    |
| Effective dose          | 0.56 ±0.07                                    |

Table 1 | Projected organ equivalent doses for $^{213}$Bi-PSMA-617 ($SV_{RBE5}/GBq$, assuming RBE = 5 for alpha and RBE = 1 for beta and photon radiation)
which was based on surrogate imaging using \(^{177}\text{Lu-PSMA-617}\) [5, 19], and is also highlighting the most dose-critical organs.

The equivalent doses in Sv RBE\(^5\) as provided in Table 1 and Table 2 were calculated assuming a relative biological effectiveness of 5 for alpha and 1 for beta and gamma radiation. Using these weightings, the contribution of alpha, beta and photon radiation is mean 98.3%, 1.5% and 0.2%, respectively, for \(^{213}\text{Bi}\), compared to 99.4% alpha, 0.5% beta and 0.1% photon radiation already reported for \(^{225}\text{Ac}\) [5].

Consisting mainly of alpha and short-range beta radiation, the absorbed dose of a particular OLINDA source organ can be considered almost directly proportional to the inverse of its mass. As provided in the Supplement/Table 1, the body weights of patients 2 and 3 (70 and 72 kg, respectively) are close to the male adult phantom (74 kg); however, patient 1 (110 kg) causes a mentionable overestimation of whole-body remainder organs. For kidney masses, the situation is similar; here patients 1 and 2 are well in line with the reference man; but in patient 3, the kidney dose should be overestimated. Neglecting individual organ masses, we have to consider a methodical uncertainty of approx. 20% for the average values of our patients. However, dose-limiting organs tend to be overestimated, which is considered the preferred bias with regard to a conservative safety dosimetry.

Assuming an acute tolerance limit of 1 Sv RBE\(^5\) for red marrow, a cumulative equivalent dose of 27 Sv RBE\(^5\) for kidneys and 17 Sv RBE\(^5\) per cycle to salivary glands [5], the maximum tolerable single fraction of \(^{213}\text{Bi-PSMA-617}\) could be projected to an activity of about 2 GBq per cycle and a cumulative treatment activity to approx. 3.6 GBq. To exploit the maximum possible cumulative dose while simultaneously keeping safety margins of the maximum single dose,

Table 2  Equivalent doses for critical organs and tumor lesions of PSMA-617 tagged with various radiolabel nuclides (\(^{225}\text{Ac}\) per MBq, \(^{213}\text{Bi}\) and \(^{177}\text{Lu}\) per GBq) assuming homogenous dose distribution

| Organ              | \(^{213}\text{Bi-PSMA-617}\) [Sv RBE\(^5\)/GBq] | \(^{213}\text{Bi-PSMA-617}\) [Sv RBE\(^5\)/1.2GBq] | \(^{225}\text{Ac-PSMA-617}\) [Sv RBE\(^5\)/MBq] Ref. [5] | \(^{225}\text{Ac-PSMA-617}\) [Sv RBE\(^5\)/7.4 MBq] | \(^{177}\text{Lu-PSMA-617}\) [Gy/GBq] Ref. [19] | \(^{177}\text{Lu-PSMA-617}\) [Gy/7.4 GBq] |
|--------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Salivary Gl.       | 8.1                             | 9.7                             | 2.3                             | 17.0                            | 1.4                             | 10.4                            |
| Kidneys            | 8.1                             | 9.7                             | 0.7                             | 5.2                             | 0.8                             | 5.9                             |
| Red marrow         | 0.52                            | 0.6                             | 0.05                            | 0.4                             | 0.03                            | 0.2                             |
| Tumor lesions      | 6.3 (3.2–9.0)                   | 7.6                             | 5.7 (1.3–9.8)                   | 42.1                            | 6.6 (6–22)                      | 48.8                            |

Fig. 2  Visualization of the different nuclide distribution taking into account the half-life of \(^{213}\text{Bi}\) (a) or \(^{225}\text{Ac}\) (b). Maximum intensity projections of \(^{68}\text{Ga-PSMA-617}\) PET scans, translated into quantitatively correct shadings using a linear gray scale normalized to time point “2 h p.i.”
fractionation regimens of, e.g. \(2 \times 1.8 \text{ GBq}, 3 \times 1.2 \text{ GBq or } 4 \times 0.9 \text{ GBq, might be necessary.}

In comparison to \(^{225}\text{Ac}-\text{PSMA-617, the ratios between tumor and all potentially dose-limiting organs are lower. The calculated results are illustrated with the maximum intensity projections of the serially performed PET scans taking into account the physical decay (Fig. 2): After 5 h, }\(^{213}\text{Bi (T}_{1/2} \text{ 46 min) already decayed by 98.9\%, and }^{225}\text{Ac (T}_{1/2} \text{ 9.9 d) only decayed by 1.5\%. Time-activity curves demonstrate how the half-life of the radiolabel and the pharmacokinetics of the shuttle molecule contribute to the tissue activity concentrations over time (Fig. 3).}

### Discussion

The aim of this work was to estimate radiation dosimetry for \(^{213}\text{Bi-PSMA-617 TAT in prostate cancer patients. Theoretically, the ratio between the absorbed dose to tumor and dose-limiting organs (kidneys, salivary glands and red marrow) was found sufficient to warrant clinical translation. Nevertheless, the therapeutic index seems clearly inferior compared to that of }^{225}\text{Ac-PSMA-617.}

It is common practice that the pharmacokinetics of therapeutic radiopharmaceuticals without sufficient inherent imaging capabilities are approximated by using a diagnostic surrogate radionuclide. \(^{68}\text{Ga\) is a positron emitter and has the advantage of high resolution, overlap-free tomographic reconstruction and possible quantification by PET. As \(^{68}\text{Ga has a minimally longer half-life than }^{213}\text{Bi, biodistribution data until near total decay of the planned therapeutics can be assessed, avoiding the common challenge that the integration to infinity has to be estimated by curve fitting. Nevertheless, the radioisotope in the chelator complex can theoretically affect the pharmacokinetics of the radiotracer and sometimes these effects are non-negligible [20]. Therefore, using \(^{68}\text{Ga-PSMA-617 imaging to approximate }^{213}\text{Bi-PSMA-617 therapy presents both a major strength and simultaneously a mentionable limitation of the used methodology.}

Another limitation is that the dosimetry of \(^{213}\text{Bi-PSMA-617 has been extrapolated from PET data, but in contrast, the dosimetry of the comparator }^{225}\text{Ac-PSMA-617 has been estimated using planar scans—a necessary compromise to cope with its longer half-life. Due to the different physical properties of both radionuclides, the kidney-absorbed dose might be over-estimated for }^{213}\text{Bi-PSMA-617. At early time points, there is still activity in cavities of kidney calices/pelvis, contributing counts to the organ VOIs during imaging. But due to the limited penetration range of the alpha particles, activity deposits there would not reach the parenchyma in the renal cortex during TAT. In contrast, images of delayed time points in }^{225}\text{Ac-PSMA-617-dosimetry should include a higher fraction of activity representing specific uptake at renal PSMA or due to reabsorption by tubular cells and must be considered more toxically relevant.}

Tumor lesion dosimetry is always challenging due to high inter-individual and even inter-lesion variability and should generally be interpreted very cautiously. In addition, the tumor dosimetry estimated for \(^{225}\text{Ac-PSMA-617 contained remarkable methodical uncertainties because the limited resolution of the underlying planar scans hampers lesion delineation,
contrast recovery and suffers from overlap, spill-out and partial volume effects. The a priori assumption that translocation of daughter nuclides can be neglected seems also more prudent for 213Bi than for the multi-step decay schema of 225Ac. However, the tumor to healthy organ ratios between 213Bi-PSMA-617 and 225Ac-PSMA-617 are in remarkably different dimensions (Table 2) and the reasons can easily be found by interpretation of the graphic images Figs. 1 and 2. As reported previously, 225Ac-PSMA-617 can benefit from continuing renal clearance beyond 5 h p.i. and further accumulation in tumor lesions with maximum uptake approximately 24 h p.i. [5]. Some preliminary case reports are also in line: Two impressive complete remissions could already be observed after 225Ac-PSMA-617 [4], but only a case of partial remission following 213Bi-PSMA-617 therapy can be found in the literature [12]. Thus, in combination with PSMA-617, 225Ac must be considered the first-choice isotope for PSMA-TAT in the setting of prostate cancer.

PSMA expression is also found in the neovasculature of other tumor entities, and especially in clear cell renal carcinoma. PSMA-PET/CT can achieve similar high uptake values as in prostate cancer [21, 22]. However, only the first hours post-injection could be assessed by PSMA-PET. Different uptake kinetics of PSMA ligands in kidneys than in prostate cancer have been reported by two different groups during preclinical experiments [23, 24] and the respective authors discussed that a reduced rate of cellular internalization in renal cells would explain these observations. Until now, tumor retention times of PSMA ligands—either in renal cancer lesions or other tumor entities—have not yet been evaluated systematically. If PSMA on the surface of renal cell cancer is indeed not sufficiently internalized after binding of a ligand, RLT based on a nuclide with multiple instable daughters, such as 225Ac, might be suboptimal. Vice versa, vascular expression could further improve target accessibility and accelerate uptake kinetics. We, therefore, should keep in mind that dosimetry of 213Bi-PSMA-617 per se allows clinical application; eventually, other clinical indications which could benefit from the specific characteristics of 213Bi-PSMA-617 may appear in the future.

Conclusion

Dosimetry of 213Bi-PSMA-617 is in a range traditionally considered promising for clinical application. However, compared to 225Ac-PSMA-617, its therapeutic index for therapy of prostate cancer appears to be inferior.

Compliance with ethical standards

Ethical approval For this type of analysis, formal consent is not required.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186thennium to 223radium. Cancer Biother Radiopharm. 2014;29:1–11.
2. Benesová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailormade DOTAtagged PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.
3. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
4. Kratochwil C, Bruchterseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4.
5. Kratochwil C, Bruchterseifer F, Rathke H, et al. Targeted alpha therapy of mCRPC with 225AcTm-PsMA-617: Dosimetry estimate and empirical dose finding. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.117.191395.
6. Juricic J, Larson SM, Sgouros G, McDevitt MR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100(4):1233–9.
7. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16(21):5303–11. https://doi.org/10.1158/1078-0432.CCR-10-0382.
8. Kratochwil C, Giesel FL, Bruchterseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radiouclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106–19. https://doi.org/10.1007/s00259-014-2857-9.
9. McDevitt MR, Barendswaard E, Mulford DA, Lai L, et al. An alphaparticle emitting antibody ((213)Bi)591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60(21):6095–100.
10. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted alpha therapy of human prostate cancer with bi-213 labeled 3591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 2002;5:36–46.
11. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA Ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation Dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705. https://doi.org/10.2967/jnumed.115.161299.
12. Sathke M, Knoesen O, Mechel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radiouclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099–100. https://doi.org/10.1007/s00259-017-3657-9.
13. Sgouros G. Bone marrow Dosimetry for Radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689–94.
14. Shen S, Meredith RF, Duan J, et al. Improved prediction of Myelotoxicity using a patient-specific imaging dose estimate for non–marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245–53.
15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.
16. Stabin MG, Konijnenberg M. Re-evaluation of absorbed fractions for photons and electrons in small spheres. J Nucl Med. 2000;41:149–60.
17. Feinendegen LE, McClure JJ. Meeting report: alpha-emitters for medical therapy—workshop of the United States Department of Energy, Denver, Colorado, may 30–31, 1996. Radiat Res. 1997;148:195–201.
18. Sgouros G, Roesske JC, McDevitt MR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.
19. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57:1170–6. https://doi.org/10.2967/jnumed.115.171397.
20. Deshmukh MV, Voll G, Kühlewein A, et al. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe¹-Tyr³-octreotide. J Med Chem. 2005;48:1506–14.
21. Baccala A, Serca L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.
22. Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82.
23. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932–40.
24. Kratochwil C, Giesel FL, Leotta K, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293–8.
25. Suliman G, Pommé S, Marouli M, et al. Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series. Applied Radiation and Isotopes 2013;77:32–37